To determine the prognosis of a PACa patient, physicians measure levels of prostate-specific antigen (PSA), and use clinical staging and the Gleason score, which is a grading system based on the architectural pattern of tissue from a PACa biopsy [4-6]. Here, KLK3 is linked to permanent neonatal diabetes mellitus-pancreatic and cerebellar agenesis syndrome.